ジフテリア・破傷風・百日咳混合ワクチンの世界市場規模：製品タイプ別、年齢層別、エンドユーザー別、地域範囲別および予測

ジフテリア、破傷風、百日咳混合ワクチンの市場規模推移と予測

ジフテリア、破傷風、百日咳混合ワクチンの市場規模は、2024年に55億46万米ドルと評価され、2026年から2032年にかけてCAGR 5.17%で成長し、2032年には82億3,255万米ドルに達すると予測されます。

• DTaPワクチンは、ジフテリア菌と破傷風菌の不活化毒素または成分と百日咳菌の抗原を含む混合ワクチンです。通常、小児期の定期予防接種の一環として、乳幼児に接種されます。このワクチンは、身体の免疫系を刺激してこれらの細菌性病原体に対する抗体を産生させ、これらの病原体が引き起こす病気に対する免疫と防御を提供します。
• ジフテリアは、重篤な呼吸器症状や生命を脅かす合併症を引き起こす可能性のある細菌感染症です。DTaPワクチンは、ジフテリア菌が産生する毒素を中和する抗体を産生するよう免疫系を刺激することで、ジフテリアを予防します。
• 破傷風は、神経系を侵し、筋肉の硬直や痙攣を引き起こす細菌感染症です。DTaPワクチンには、破傷風の原因菌であるクロストリジウム・テタニが産生する毒素に対する免疫を誘導する成分が含まれています。
• 百日咳は、激しい咳発作を特徴とする伝染性の呼吸器感染症です。DTaPワクチンには百日咳菌の抗原が含まれており、百日咳感染から身を守る抗体の産生を刺激します。
• 現在進行中の研究は、有効性、安全性、防御期間を向上させたDTaPワクチンの改良型製剤の開発を目指しています。これには、免疫反応を最適化し、副作用を軽減するための新しいアジュバント、送達システム、抗原の組み合わせの開発が含まれます。

ジフテリア・破傷風・百日咳混合ワクチン市場力学

世界のジフテリア・破傷風・百日咳混合ワクチン市場を形成している主な市場力学は以下の通り：

主な市場促進要因

• ワクチン接種に対する意識の高まり：ジフテリア、破傷風、百日咳のような疾患の予防におけるワクチン接種の重要性に対する保護者、介護者、医療従事者の意識の高まりが、教育キャンペーンや公衆衛生イニシアティブに後押しされたDTaPワクチンの需要急増につながり、市場拡大につながりました。
• 百日咳の発生率の増加：百日咳の流行は、複雑な疾病伝播と集団免疫の達成における課題の結果です。要因としては、免疫力の低下、ワクチン接種率の不完全さ、百日咳菌の進化などが挙げられます。診断が困難であるため、治療が遅れ、感染のリスクが高まる。百日咳患者の増加が市場の成長を可能にします。
• ヘルスケア支出の増加：新興経済諸国におけるヘルスケア支出の増加は、予防対策、特にワクチン接種プログラムへの投資を促進しています。ヘルスケアプロバイダーは、政府機関や国際機関との提携を通じて、特にサービスが行き届いていない遠隔地でのワクチン接種と配布を広く確保しています。予防医療対策、特にワクチン接種プログラムに対するこうした取り組みの高まりが、市場の成長を後押ししています。
• ワクチン製剤の進歩：革新的な製剤戦略、アジュバント、抗原提示システム、送達メカニズムの強化によりDTaPワクチンの性能が向上しており、安定性、保存期間、投与の簡便性が改善され、市場拡大が促進されています。

主な課題

• ワクチンの供給不足：機器の故障や品質管理上の問題など、製造上の混乱はDTaPワクチンの製造を妨げ、不十分な供給量につながる可能性があります。輸送の遅延や保管の問題など、サプライチェーンの混乱は供給不足を悪化させ、ヘルスケア施設やワクチン接種施設へのタイムリーな流通を妨げ、混合ワクチンの製造・供給に支障をきたす可能性があります。
• コールドチェーン管理の課題：コールドチェーン管理はワクチンの有効性にとって極めて重要であるが、気温の変動は有効性を損なう可能性があります。電気、冷蔵、輸送インフラへのアクセスが限られている遠隔地では、コールドチェーン管理におけるさらなる課題に直面します。適切な取り扱いプロトコルの欠如が、ジフテリア・破傷風・百日咳混合ワクチン市場をさらに制限しています。
• コストに関する懸念：ジフテリア・破傷風・急性百日せき混合ワクチンは、資源の制約、入手可能性の制限、物流の障害、価格の問題などから、中低所得国では入手が困難です。このことがワクチン接種の妨げとなり、予防接種率の格差を拡大する可能性があります。ヘルスケア施設は、安定した在庫を維持するのに苦労しており、特に弱い立場にある子どもたちへの予防接種の機会を逃しています。特に遠隔地やサービスが行き届いていない地域での流通ロジスティクスは、混合ワクチン市場の成長を阻害する可能性があります。

主な動向

• ワクチン製剤の改良：DTaPワクチンは、製剤、安全性、予防期間を改善するために継続的な研究が行われています。これには、免疫反応を最適化し、副作用を最小限に抑えるための新規アジュバント、送達メカニズム、抗原の組み合わせの研究が含まれ、市場成長の機会を生み出しています。
• 研究開発：研究では、有効性、安全性、利用しやすさを向上させるため、DTaPワクチン技術が進歩しています。その一つがmRNAワクチン技術で、合成mRNA分子を用いて特定の抗原を産生し、強固な免疫反応を引き起こすものです。このアプローチは、迅速な開発、拡張性、免疫原性の向上をもたらします。ウイルス様粒子、リポソーム、ナノ粒子キャリアのような新しい抗原デリバリー・プラットフォームも研究されています。
• 混合ワクチン：DTaPワクチンのような混合ワクチンの開発は、単一の製剤でより広範囲の感染症に対する防御を提供できる可能性があるため、関心が高まっています。

目次

第1章 世界のDTaP混合ワクチン市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のDTaP混合ワクチン市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 DTaP混合ワクチンの世界市場：製品タイプ別

• 概要
• DTaP
• TD
• Tdap

第6章 DTaP混合ワクチンの世界市場：年齢層別

• 概要
• 成人
• 小児

第7章 DTaP混合ワクチンの世界市場：エンドユーザー別

• 概要
• 病院
• 診療所
• ワクチン接種センター

第8章 DTaP混合ワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界のDTaP混合ワクチン市場競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• Bionet-Asia
• Johnson & Johnson
• GlaxoSmithKline plc
• Mass biologics
• Meiji Holdings Co., Ltd.
• Merck & Co., Inc.
• Panacea Biotech Ltd.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• namely AJ Vaccines

第11章 企業プロファイル付録

• 関連調査

Diphtheria, Tetanus And Acellular Pertussis Combined Vaccine Market Size And Forecast

Diphtheria, Tetanus And Acellular Pertussis Combined Vaccine Market size was valued at USD 5500.46 Million in 2024 and is projected to reach USD 8232.55 Million by 2032, growing at a CAGR of 5.17% from 2026 to 2032.

• The DTaP vaccine is a combination vaccine that contains inactivated toxins or components of the diphtheria and tetanus bacteria, as well as antigens from the Bordetella pertussis bacterium. It is administered through a series of shots typically given to infants and young children as part of routine childhood immunization schedules. The vaccine stimulates the body's immune system to produce antibodies against these bacterial pathogens, providing immunity and protection against the diseases they cause.
• Diphtheria is a bacterial infection that can cause severe respiratory symptoms and potentially life-threatening complications. The DTaP vaccine helps prevent diphtheria by stimulating the immune system to produce antibodies that neutralize the toxins produced by the bacterium Corynebacterium diphtheriae.
• Tetanus is a bacterial infection that affects the nervous system, leading to muscle stiffness and spasms. The DTaP vaccine includes a component that induces immunity against the toxin produced by the bacterium Clostridium tetani, which causes tetanus.
• Pertussis is a highly contagious respiratory infection characterized by severe coughing fits. The DTaP vaccine contains antigens from Bordetella pertussis, which stimulate the production of antibodies to protect against pertussis infection.
• Ongoing research aims to develop improved formulations of the DTaP vaccine with enhanced efficacy, safety, and duration of protection. This includes the development of newer adjuvants, delivery systems, and antigen combinations to optimize immune responses and reduce side effects.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Dynamics

The key market dynamics that are shaping the global diphtheria, tetanus, and acellular pertussis combined vaccine market include:

Key Market Drivers:

• Growing Awareness about Vaccination: The growing awareness of the importance of vaccination in preventing diseases like diphtheria, tetanus, and pertussis among parents, caregivers, and healthcare practitioners has led to a surge in demand for DTaP vaccines, fueled by educational campaigns and public health initiatives, resulting in market expansion.
• Increasing Incidence of Pertussis: Pertussis outbreaks are a result of complex disease transmission and challenges in achieving herd immunity. Factors include waning immunity, incomplete vaccination coverage, and the evolution of Bordetella pertussis. Diagnosis is difficult, leading to treatment delays and increased risk of transmission. Rising cases of pertussis enable market growth.
• Growing Healthcare Expenditure: The rise in healthcare expenditure in developing economies is driving investments in preventive measures, particularly vaccination programs. Healthcare providers, through partnerships with government agencies and international organizations, ensure widespread vaccine access and distribution, especially in underserved and remote areas. This growing commitment to preventive healthcare measures, particularly vaccination programs, is boosting market growth.
• Growing advancements in vaccine formulations: Research is enhancing DTaP vaccine performance through innovative formulation strategies, enhancing adjuvants, antigen presentation systems, and delivery mechanisms, leading to improved stability, shelf-life, and administration ease, thereby promoting market expansion.

Key Challenges:

• Vaccine Supply Shortages: Manufacturing disruptions, such as equipment malfunctions or quality control issues, can impede the production of DTaP vaccines, leading to inadequate supply levels. Supply chain disruptions, like transportation delays or storage issues, can exacerbate shortages and hinder timely distribution to healthcare facilities and vaccination sites, thereby challenging the manufacturing and supply of the combined vaccine.
• Cold Chain Management Challenges: Cold chain management is crucial for vaccine efficacy, but temperature fluctuations can compromise effectiveness. Remote areas with limited access to electricity, refrigeration, and transportation infrastructure face additional challenges in cold chain management. Lack of proper handling protocols further restricts the combined diphtheria, tetanus, and acellular pertussis vaccine market.
• Concerns Regarding Costing: DTaP vaccines are challenging to access in low- and middle-income countries due to resource constraints, limited availability, logistical hurdles, and affordability issues. This can impede vaccination efforts and increase immunization coverage disparities. Healthcare facilities struggle to maintain consistent stocks, leading to missed vaccination opportunities, especially for vulnerable children. Distribution logistics, particularly in remote or underserved areas, may hinder the combined vaccine market growth.

Key Trends:

• Improved Vaccine Formulations: The DTaP vaccine is under continuous research to improve its formulations, safety, and protection duration. This involves exploring novel adjuvants, delivery mechanisms, and antigen combinations to optimize immune responses and minimize side effects, creating market growth opportunities.
• Research and Development: Research is advancing DTaP vaccine technology to improve efficacy, safety, and accessibility. One innovation is mRNA vaccine technology, which uses synthetic mRNA molecules to produce specific antigens, triggering robust immune responses. This approach offers rapid development, scalability, and enhanced immunogenicity. Novel antigen delivery platforms like virus-like particles, liposomes, and nanoparticle carriers are also being explored.
• Combination Vaccines: The development of combination vaccines, such as the DTaP vaccine, is gaining interest due to its potential to offer protection against a wider range of infectious diseases in a single formulation.

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global diphtheria, tetanus, and acellular pertussis combined vaccine market:

North America:

• North America is poised to maintain a substantial stake in the DTaP combined vaccine market, propelled by its robust healthcare infrastructure, elevated vaccination rates, and comprehensive government-driven immunization campaigns.
• The region benefits from cutting-edge technological advancements, fortified by stringent regulatory frameworks, which collectively bolster the market's growth trajectory.
• Moreover, heightened disease awareness among both healthcare professionals and the general populace further amplifies the demand for DTaP vaccines in North America.
• This comprehensive ecosystem fosters a conducive environment for the continued expansion of the DTaP Combined Vaccine Market, ensuring widespread accessibility and efficacy of preventive healthcare measures against diphtheria, tetanus, and pertussis throughout the region.

Europe:

• Europe stands out as a significant market for DTaP vaccines, distinguished by its well-established vaccination policies, comprehensive immunization coverage, and proactive approaches to disease prevention.
• Europe's commitment to research and development (R&D) fosters innovation in vaccine technology and formulation. Increasing investments in R&D initiatives, alongside collaborations between public health agencies, academic institutions, and vaccine manufacturers, drive advancements in DTaP vaccine development.
• Europe's proactive disease prevention strategies focus on early detection, surveillance, and response to infectious diseases, including those preventable by vaccination.
• Strong partnerships between public health authorities and healthcare providers enhance disease surveillance efforts, enabling timely interventions to control disease outbreaks and minimize their impact on public health.

Asia Pacific:

• Rapid urbanization and population growth in countries like China, India, and Japan further contribute to the expansion of the DTaP Combined Vaccine Market. As urban populations increase, so does the demand for healthcare services, including immunization.
• Governments in these countries are implementing initiatives to strengthen healthcare infrastructure and improve access to healthcare services in both urban and rural areas, thereby facilitating the expansion of immunization programs.
• Additionally, government initiatives aimed at enhancing healthcare infrastructure play a crucial role in driving market expansion.
• Investments in healthcare facilities, vaccination clinics, and cold chain logistics contribute to the efficient delivery and distribution of DTaP vaccines, ensuring that they reach remote and underserved areas.

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market: Segmentation Analysis

The Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market is segmented based on Product Type, Age Group, End User, And Geography.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Product Type

• DTaP Vaccines
• TD Vaccines
• Tdap Vaccines

Based on Product Type, the market is categorized into DTaP, TD, and Tdap. The DTaP segment dominated the global DTP vaccine market. The demand for DTaP and pertussis vaccines is driving global growth. WHO states immunization can prevent 3.5-5 million deaths annually. Since vaccines were introduced, few respiratory diphtheria cases have been reported by the CDC. Unvaccinated travelers face high infection risks, so governments mandate immunization for travelers visiting countries with infectious diseases. According to WHO In 2022, Coverage of a third dose of a vaccine protecting against diphtheria, tetanus, and pertussis (DTP3) recovered from 81% in 2021 to 84% in 2022. High birth rates, government initiatives, and insurance drive the DTaP vaccine market growth.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Age Group

• Adult Vaccines
• Pediatric Vaccines

Based on Age Group, the DTP vaccines market is segmented into Pediatric Vaccines and Adult Vaccines. By age group, the market for vaccines for adults is expected to experience significant growth due to the increase in infectious diseases among adults. Moreover, the segment is likely to see an upsurge in growth due to advancements in research and development and a strong product pipeline during the forecast period. However, the pediatric segment currently dominates the market due to the high demand for DTP vaccines among infants. The pediatrics vaccines segment's potential size is based on the fact that the global birth rate is increasing, boosting the demand for pediatric vaccines.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By End-User

• Hospitals
• Clinics
• Vaccination Centre

Based on End-User, the market is fragmented into Hospitals, Clinics, and Vaccination Centre. The hospital segment dominated the largest market share throughout the forecast period. Hospitals play a pivotal role as primary healthcare providers, offering a wide array of medical services, including immunization. As key end-users of DTaP vaccines, hospitals serve as vital hubs for administering preventive healthcare measures to individuals across all age groups, from newborns to adults. Their significance lies in their ability to provide comprehensive vaccination services, encompassing routine immunizations as well as rapid responses to disease outbreaks.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Diphtheria, Tetanus, And Acellular Pertussis Combined Vaccine is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share of Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccines. Well-established healthcare infrastructure, high vaccination rates, and robust immunization programs contribute to the dominance of the DTP vaccine market. Moreover, ongoing advancements in medical technology and strong regulatory frameworks further bolster market growth in this region.

Key Players

• The "Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, namely AJ Vaccines, and GlaxoSmithKline plc. Merck & Co. Inc., Sanofi, Bionet-Asia, Mass biologics, Meiji Holdings Co., Ltd., Panacea Biotech Ltd., and Serum Institute of India Pvt. Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Recent Developments
• In October 2022, the FDA approved Boostrix for pregnant women in their third trimester to prevent pertussis in infants under 2 months old.
• In June 2021, Merck and Sanofi's VAXELIS, the first and only six-in-one pediatric combination vaccine, is now available in the U.S. The vaccine is approved for use in children aged 6 weeks to 4 years to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DTaP COMBINED VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DTaP COMBINED VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DTaP COMBINED VACCINE MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 DTaP
• 5.3 TD
• 5.4 Tdap

6 GLOBAL DTaP COMBINED VACCINE MARKET, BY AGE GROUP

• 6.1 Overview
• 6.2 Adult
• 6.3 Pediatric

7 GLOBAL DTaP COMBINED VACCINE MARKET, BY END USER

• 7.1 Overview
• 7.2 Hospitals
• 7.3 Clinics
• 7.4 Vaccination Centers

8 GLOBAL DTaP COMBINED VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL DTaP COMBINED VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Bionet-Asia
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Johnson & Johnson
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 GlaxoSmithKline plc
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Mass biologics
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Meiji Holdings Co., Ltd.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Merck & Co., Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Panacea Biotech Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Sanofi
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Serum Institute of India Pvt. Ltd.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 namely AJ Vaccines
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research